Press Releases - Sami Labs

Disclaimer

US-FDA: This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

Usage disclaimer: The information pertaining to any marketing materials by Sabinsa, is for general purposes only. Users are urged to check the validity of patents if any, on any Sabinsa items for their intended use.

EFSA: This statement has not been evaluated by the EFSA. This product is not intended to diagnose, treat, cure, or prevent any disease.

Australia: Please note as an ingredient supplier the information contained in this website is for marketers of finished products formulations and is not intended as consumer advice. Marketers should ensure finished products are lawful and comply with the regulations of the countries in which these items are sold. Every care has been taken to ensure the accuracy of the information provided at the time of publication.

X Close

Sabinsa’s Four Indian Manufacturing Sites Achieve FSSC 22000 Certification

New Research Expands upon Use of Sabinsa’s Curcumin C3 Complex® as an Adjunct to Chemotherapy

Sabinsa’s Curcumin C3 Reduct® Self-Affirmed GRAS

Sabinsa Achieves USP GMP Audited Status for Three Additional Sites

Published Analysis of Curcumin Research Provides Comprehensive Overview

Sabinsa’s Manufacturing Arm Receives Research Funding From The Government of India

ABOUT SAMI LABS

HEADQUARTERS

CERTIFICATES

CONTACT US